Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a clinical-stage biotechnology company, announced continued progress on its proprietary AI platform and robotics integration as it approaches initial commercial deployment. The company has integrated approximately 28 million scientific abstracts into its PDAOAI platform and combined it with robotics developed alongside TechForce Robotics, enabling real-time, automated workflows designed to improve efficiency and support compliance in pharmaceutical development and manufacturing.
The PDAOAI platform supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration. By leveraging this technology, Oncotelic aims to streamline drug development and manufacturing, potentially reducing costs and time-to-market for new therapies. The integration of robotics further enhances automation, ensuring consistent and compliant operations.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. The company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents.
Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic's position in oncology and rare disease therapeutics.
The advancement of Oncotelic's AI and robotics platform signals a significant step toward modernizing pharmaceutical development. By automating workflows and integrating vast scientific data, the company aims to enhance efficiency and regulatory compliance, which could have broad implications for the industry. For investors and stakeholders, this progress may indicate potential improvements in operational performance and drug development timelines.
For more information, visit https://ibn.fm/OTLC for the latest news and updates regarding OTLC.
